RAPT Therapeutics, Inc. (RAPT)
Largest Insider Buys in Sector
RAPT Stock Price History Chart
RAPT Stock Performance
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 …
Insider Activity of RAPT Therapeutics, Inc.
Over the last 12 months, insiders at RAPT Therapeutics, Inc. have bought $0 and sold $95,236 worth of RAPT Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at RAPT Therapeutics, Inc. have bought $3.7M and sold $29.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $97,612 was made by Robbins Wendye (director) on 2023‑03‑14.
List of Insider Buy and Sell Transactions, RAPT Therapeutics, Inc.
| 2024-01-05 | Sale | CHIEF SCIENTIFIC OFFICER | 898 0.0025% | $22.78 | $20,456 | -81.44% | ||
| 2023-12-21 | Sale | Chief Medical Officer | 2,500 0.007% | $21.68 | $54,200 | -79.23% | ||
| 2023-11-28 | Sale | Chief Medical Officer | 1,500 0.0042% | $13.72 | $20,580 | -44.32% | ||
| 2023-10-03 | Sale | Chief Medical Officer | 2,500 0.0072% | $15.77 | $39,425 | -43.25% | ||
| 2023-08-18 | Sale | Chief Medical Officer | 2,500 0.0072% | $18.92 | $47,300 | -38.45% | ||
| 2023-04-19 | Sale | Chief Medical Officer | 5,000 0.015% | $18.88 | $94,400 | -1.14% | ||
| 2023-03-14 | director | 5,000 0.0152% | $19.52 | $97,612 | -2.84% | |||
| 2023-03-07 | Sale | 5,000 0.015% | $29.62 | $148,100 | -36.53% | |||
| 2023-01-24 | Sale | Chief Medical Officer | 5,000 0.0162% | $30.00 | $150,000 | -31.27% | ||
| 2023-01-19 | Sale | Chief Medical Officer | 5,000 0.0146% | $25.56 | $127,800 | -27.26% | ||
| 2023-01-05 | Sale | Chief Scientific Officer | 742 0.0022% | $21.97 | $16,299 | -13.46% | ||
| 2022-12-29 | Sale | Chief Medical Officer | 5,000 0.0132% | $18.03 | $90,150 | +2.33% | ||
| 2022-11-28 | Sale | Chief Medical Officer | 5,000 0.0144% | $17.87 | $89,350 | +10.70% | ||
| 2022-11-02 | Sale | Chief Medical Officer | 5,000 0.0144% | $22.32 | $111,600 | -10.51% | ||
| 2022-10-13 | Sale | Chief Medical Officer | 2,000 0.0054% | $21.52 | $43,040 | -10.07% | ||
| 2022-08-30 | Sale | Chief Medical Officer | 2,500 0.0079% | $28.13 | $70,325 | -20.41% | ||
| 2022-07-11 | Sale | Chief Medical Officer | 2,000 0.006% | $19.95 | $39,900 | +6.92% | ||
| 2022-05-25 | 1,837 0.0054% | $12.45 | $22,880 | +54.33% | ||||
| 2022-05-25 | 63 0.0002% | $12.45 | $785 | +54.33% | ||||
| 2022-05-23 | 15,776 0.0484% | $12.00 | $189,345 | +67.60% |
Insider Historical Profitability
| GOEDDEL DAVID V | director | 4982333 14.2746% | $2.60 | 1 | 0 | +107.48% |
| Topspin Fund L.P. | director | 2575371 7.3785% | $2.60 | 1 | 0 | +107.48% |
| Column Group LLC | 1236261 3.5419% | $2.60 | 3 | 0 | +69.16% | |
| Wong Brian Russell | President and CEO | 337000 0.9655% | $2.60 | 2 | 1 | +43.65% |
| TCG IV GP, LLC | 42189 0.1209% | $2.60 | 3 | 0 | +69.16% |
Institutional Investor Ownership
| Fidelity Investments | $46.87M | 15 | 5.22M | +35.81% | +$12.36M | <0.01 | |
| Column Group Llc | $24.07M | 7.7 | 2.68M | 0% | +$0 | 18.28 | |
| The Vanguard Group | $22.39M | 7.16 | 2.49M | +21.23% | +$3.92M | <0.0001 | |
| BlackRock | $22.2M | 7.1 | 2.47M | +0.78% | +$171,553.91 | <0.0001 | |
| T. Rowe Price | $18.21M | 5.83 | 2.03M | -40.59% | -$12.44M | <0.01 |